Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4) | Zendy

Valérie Potard | Zendy; Anne Simon | Zendy; JeanMarc Lacombe | Zendy; JeanJacques Parienti | Zendy; Dominique Costagliola | Zendy

Open Access

Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4)

Author(s) -

Valérie Potard,

Anne Simon,

JeanMarc Lacombe,

JeanJacques Parienti,

Dominique Costagliola

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw498

Subject(s) - raltegravir , medicine , hazard ratio , regimen , clinical endpoint , confidence interval , cohort , viral load , confounding , proportional hazards model , randomized controlled trial , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy

In individuals with viral load (VL) suppression on a boosted protease inhibitor (PI) regimen, a switch to raltegravir (RAL) can be an option in case of comorbidities, but the SWITCHMRK trials challenged this strategy. Here, among individuals with VL suppression on a boosted PI, we compared outcomes between those who continued on the same regimen and those who switched to RAL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research